A prospective study of suicidal behavior in young patients of depressive episodes with hidden bipolarity exposed to selective serotonin reuptake inhibitor

Treatment of depressive episodes in young patients is challenging owing to several reasons such as poor diagnostic stability and atypical presentation. Evidence regarding treating such patients with antidepressants such as selective serotonin reuptake inhibitor (SSRI) is not clear. Fifty patients ag...

Full description

Saved in:
Bibliographic Details
Published inIndian journal of psychiatry Vol. 66; no. 2; pp. 195 - 198
Main Authors Kumar, Manoj, Acharya, Rudraprasad, Mallik, Nitu, Pal, Arghya, Ghosal, Malay Kumar
Format Journal Article
LanguageEnglish
Published India Medknow Publications and Media Pvt. Ltd 01.02.2024
Medknow Publications & Media Pvt. Ltd
Wolters Kluwer - Medknow
Subjects
Antidepressants
Antidepressants, Tricyclic
Brief Research Communication
Care and treatment
Depression, Mental
Health aspects
Medical research
Medicine, Experimental
Patient compliance
Patients
Phenols
Psychological aspects
Serotonin uptake inhibitors
Suicidal behavior
Suicidal ideation
Suicides & suicide attempts
SSRI
bipolar disorder
depression
Adolescent
suicide
Online AccessGet full text

Cover

More Information
Summary:Treatment of depressive episodes in young patients is challenging owing to several reasons such as poor diagnostic stability and atypical presentation. Evidence regarding treating such patients with antidepressants such as selective serotonin reuptake inhibitor (SSRI) is not clear. Fifty patients aged 10-24 years diagnosed with depressive episodes and drug-free for at least 3 months were rated on Beck's Depression Inventory (BDI), The Mood Disorder Questionnaire (MDQ), and Beck Scale for Suicidal Ideation (BSS). The scores of BSS and BDI were compared across four timeframes (weeks 0, 2, 4, and 6) for MDQ-positive and negative patients by using the generalized estimating equations model. Patients who were MDQ-positive (11 patients) tended to score higher on BDI (at weeks 2 and 4) and BSS (at weeks 2, 4, and 6) as compared to MDQ-negative patients (39 patients). After being started on SSRI, MDQ-positive patients showed a poorer response as compared to the other group. The small sample size and short follow-up duration were the major limitations. Close clinical monitoring with regular follow-up during antidepressant initiation is recommended to reduce the risk of suicidality.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0019-5545
1998-3794
DOI:10.4103/indianjpsychiatry.indianjpsychiatry_221_23